Simple Structure-Based Approach for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease

Beta-site amyloid precursor protein cleaving enzyme-1 (BACE1) is a target of interest for treating patients with Alzheimer's disease (AD). Inhibition of BACE1 may prevent amyloid-ß (Aß) plaque formation and the development or progression of Alzheimer's disease. Known BACE1 inhibitors were analyzed using computational chemistry and cheminformatics techniques to search for quantitative structure-activity relationships (QSAR). A remarkable relationship was found with only two simple descriptors. The square of the linear correlation coefficient r(2) is 0.75. The main descriptor is the number of hydrophobic contacts in the range 4-5 Å between the atoms of the ligand and active site. The other descriptor is the number of short (<2.8 Å) hydrogen bonds. Our approach uses readily available structural data on protein-inhibitor complexes in the Protein Data Bank (PDB) but would be equally applicable to proprietary structural biology data. The findings can aid structure-based design of improved BACE-1 inhibitors. If an inhibitor has less observed activity than predicted by our correlation, the compound should be retested because the first assay may have underestimated the compound's true activity.

[1]  Rajiv Chopra,et al.  Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. , 2010, Journal of medicinal chemistry.

[2]  I. Melnikova.  Therapies for Alzheimer's disease , 2007, Nature Reviews Drug Discovery.

[3]  Qing Zhang,et al.  The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications , 2005, BMC Bioinformatics.

[4]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[5]  Donald B. Boyd.  Is Rational Design Good for Anything , 1999 .

[6]  Lin Hong,et al.  Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. , 2004, Biochemistry.

[7]  Stephen Hanessian,et al.  Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[8]  Katrin Stierand,et al.  Drawing the PDB: Protein-Ligand Complexes in Two Dimensions. , 2010, ACS medicinal chemistry letters.

[9]  Xun Li,et al.  Interpretation of the Binding Affinities of PTP1B Inhibitors with the MM-GB/SA Method and the X-Score Scoring Function , 2009, J. Chem. Inf. Model..

[10]  I. Muegge.  PMF scoring revisited. , 2006, Journal of medicinal chemistry.

[11]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[12]  X Chen,et al.  BindingDB: a web-accessible molecular recognition database. , 2001, Combinatorial chemistry & high throughput screening.

[13]  Michael G. Lerner,et al.  Binding MOAD (Mother Of All Databases) , 2005, Proteins.

[14]  Nanda Ghoshal,et al.  Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies , 2010, J. Comput. Aided Mol. Des..

[15]  K. Jacobson,et al.  Small molecule blockers of the Alzheimer Aβ calcium channel potently protect neurons from Aβ cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[16]  R. Todeschini,et al.  Molecular Descriptors for Chemoinformatics: Volume I: Alphabetical Listing / Volume II: Appendices, References , 2009 .

[17]  Lin Hong,et al.  Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. , 2007, Journal of medicinal chemistry.

[18]  Raed A. Al‐Qawasmeh,et al.  Design, synthesis, and qualitative structure-activity evaluations of novel β-secretase inhibitors as potential Alzheimer's drug leads. , 2011, Journal of medicinal chemistry.

[19]  D. Riddell,et al.  BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs). , 2008, Bioorganic & medicinal chemistry letters.

[20]  Min Xu,et al.  Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). , 2006, Journal of medicinal chemistry.

[21]  Romano Silvestri,et al.  Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease , 2009, Medicinal research reviews.

[22]  T. Lefebvre.  Neurodegeneration: Recall sugars, forget Alzheimer's. , 2012, Nature chemical biology.

[23]  Katrin Stierand,et al.  Molecular complexes at a glance: automated generation of two-dimensional complex diagrams , 2006, Bioinform..

[24]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[25]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[26]  D. B. Boyd,et al.  Electronic structures of cephalosporins and penicillins. 11. Parabolic relationships between antibacterial activity of cephalosporins and .beta.-lactam reactivity predicted from molecular orbital calculations , 1980 .

[27]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[28]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[29]  Y. Martin,et al.  A general and fast scoring function for protein-ligand interactions: a simplified potential approach. , 1999, Journal of medicinal chemistry.

[30]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[31]  D. Riddell,et al.  BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character. , 2008, Bioorganic & medicinal chemistry letters.

[32]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[33]  Gianni Chessari,et al.  Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.

[34]  H. Guy,et al.  Theoretical models of the ion channel structure of amyloid beta-protein. , 1994, Biophysical journal.

[35]  M. Taha,et al.  Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads. , 2010, Bioorganic & medicinal chemistry.

[36]  Luhua Lai,et al.  Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..

[37]  Richard D. Smith,et al.  Binding MOAD, a high-quality protein–ligand database , 2007, Nucleic Acids Res..

[38]  Arun K. Ghosh,et al.  Memapsin 2 (beta-secretase) inhibitors: drug development. , 2008, Current Alzheimer research.

[39]  Zhihai Liu,et al.  Comparative Assessment of Scoring Functions on a Diverse Test Set , 2009, J. Chem. Inf. Model..

[40]  Hank F Kung,et al.  The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing. , 2012, ACS medicinal chemistry letters.

[41]  D. Small,et al.  Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions , 2010, Biological chemistry.

[42]  R. Heinrikson,et al.  Human β-Secretase (BACE) and BACE Inhibitors , 2003 .